Concepedia

Author

Michael Song

Janssen (United States)ORCID

Also Known As

M Song, M. Song, Michael SONG, Michael Song

68

Publications

3.3K

Citations

24

H-Index

10

Concepts

All Affiliations

Janssen (United States)University of Southern CaliforniaSt Vincent's Hospital MelbourneSkin and Cancer FoundationMemorial University of Newfoundland
MS

About

Michael Song is an author at Janssen (United States) specializing in dermatology, medicine, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

367

2

Immunology

1

1

100

3

Autoimmune Disease

1

1

210

4

Clinical Trials

1

1

210

5

Immunotherapy

1

1

100

Michael Song

×

30

Publications

3.2K

Citations

24

H-Index

YearCitations

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley,

Journal of the American Academy of Dermatology

2017

712

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin,

British Journal of Dermatology

2017

336

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh, Christopher T. Ritchlin, Proton Rahman,

Annals of the Rheumatic Diseases

2014

293

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

Tsen‐Fang Tsai, Ji‐Chen Ho, Michael Song,

Journal of Dermatological Science

2011

210

Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial

Atsuyuki Igarashi, Takeshi Kato, Mai Kato,

The Journal of Dermatology

2011

203

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Arthur Kavanaugh, L. Puig, Alice B. Gottlieb,

Annals of the Rheumatic Diseases

2016

154

Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4</sub>R‐antagonist (<scp>JNJ</scp>‐39758979) in<scp>J</scp>apanese adults with moderate atopic dermatitis

Yoko Murata, Michael Song, Hisayuki Kikuchi,

The Journal of Dermatology

2014

127

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions

Peter Foley, Kenneth B. Gordon, C.E.M. Griffiths,

JAMA Dermatology

2018

117

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial

Arthur Kavanaugh, L. Puig, Alice B. Gottlieb,

Arthritis Care & Research

2015

105

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Kenneth B. Gordon, April W. Armstrong, Peter Foley,

Journal of Investigative Dermatology

2019

100

Page 1